• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov19
H.C. Wainwright Analyst Reiterates Buy Rating on Agios Pharma and Sets Target Price
17:54
Agios Announces Topline Results of Mitapivat Phase 3 Trial in Sickle Cell Disease
12:26
Nov13
Agios Pharmaceuticals' Chief Medical Officer Reports Common Stock Disposition
21:10
Oct30
Agios Pharmac released FY2025 Q3 earnings on October 30 Pre-Market EST, actual revenue USD 12.88 M (forecast USD 10.61 M), actual EPS USD -1.7799 (forecast USD -1.8961)
13:30
Agios Pharmaceuticals released FY2025 9 Months earnings on October 30 Pre-Market (EST), actual revenue USD 34.06 M, actual EPS USD -5.2675
13:30
Agios Pharmaceuticals Reports Q3 2025 Earnings and Drug Application Progress
10:33

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 12.88 M, Net Income -103.43 M, EPS -1.7799

Jul31
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 12.46 M, Net Income -112.02 M, EPS -1.9336

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 8.726 M, Net Income -89.29 M, EPS -1.5539

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
HYNE
14.000
+40.00%
+4.000
ASTX
46.070
+36.50%
+12.320
View More